Intercept Pharma's new liver disease drug comes with hefty price tag: $70000 a year - MarketWatch

MarketWatch

Intercept Pharma's new liver disease drug comes with hefty price tag: $70000 a year MarketWatch For the last two decades, there's been little recourse for patients with the rare, chronic disease primary biliary cholangitis — which causes the liver to deteriorate — who didn't respond well to the only treatment option. Those patients, up to 40 ... Here's Why Intercept Pharma (ICPT) Stock Is Gaining TodayTheStreet.com FDA approves Ocaliva for rare, chronic liver diseaseFDA.gov Intercept Pharmaceuticals (ICPT) PT Trimmed to $140 at Leerink PartnersStreetInsider.com Pharmacy Times -Bidness ETC -Benzinga -CNA Finance (press release) all 20 news articles »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNHL-tVmk9t7Q7fKfN3mNd1Pf-KXyQ&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779123871458&ei=PdBNV7DSCYeM3wGonoKYBg&url=http://www.marketwatch.com/story/intercept-pharmas-new-liver-disease-drug-comes-with-hefty-price-tag-70000-a-year-2016-05-31
via IFTTT